Inspire Medical Systems Faces Class Action, Stock Plummets 32.35%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Lawsuit Reminder: Kirby McInerney LLP reminds investors that January 5, 2026, is the deadline to seek lead plaintiff appointment in the class action for those who acquired Inspire securities between August 6, 2024, and August 4, 2025.
- Weak Demand: The lawsuit alleges that Inspire failed to disclose poor demand for its implantable medical device, leading many treatment centers to continue using earlier versions instead of transitioning to the new treatment.
- Earnings Downgrade: On August 4, 2025, Inspire revealed that it would reduce its 2025 earnings guidance by over 80% due to low demand and excess inventory, significantly undermining investor confidence.
- Stock Plunge: Following the negative news, Inspire's stock price dropped from $129.95 to $87.91, a decline of 32.35%, indicating a pessimistic outlook on the company's future prospects.
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSP is 115.58 USD with a low forecast of 82.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 93.670
Low
82.00
Averages
115.58
High
180.00
Current: 93.670
Low
82.00
Averages
115.58
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
